ArticleWorld journal of diabetes2022
Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic
Article in World journal of diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Exploring the mechanism of Shenhua tablet alleviating renal injury by regulating macrophage glycolysis hypoxia-inducible factor-1α/ pyruvate kinase M2 signaling pathway in diabetic kidney disease mice.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- The mechanisms and therapeutic potential of clopidogrel in mitigating diabetic cardiomyopathy in db/db mice.iScience · 2024Article
- Tanshinone IIA Promoted Autophagy and Inhibited Inflammation to Alleviate Podocyte Injury in Diabetic Nephropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Article
- Mass cytometry reveals the corneal immune cell changes at single cell level in diabetic mice.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy (DN) is the principal cause of end-stage renal disease. Previous studies have shown that clopidogrel can prevent the early progression of renal injury.
aimTo elucidate whether clopidogrel is beneficial against DN by using a
methods
resultsClopidogrel treatment did not affect the body mass or blood glucose level of the
conclusionClopidogrel significantly reduced renal collagen deposition and fibrosis and prevented renal dysfunction in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.